hpn328
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 2020 (NCT04471727)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Delta-like protein 3INHIBITOR
DLL3 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068123 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07227597 | Phase 1/Phase 2 (Phase 2) | Dec 12, 2025 | Daiichi Sankyo, Merck |
| NCT06780137 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2025 | Daiichi Sankyo, Merck |
| NCT04471727 | Phase 1/Phase 2 (Phase 2) | Nov 2, 2020 | Harpoon Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 2 | 0 | 1 | 2025 |
| Merck | For profit | 2 | 2 | 1 | 2025 |
| Harpoon Therapeutics | For profit | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1